Tofacitinib (CP-690550,Tasocitinib)
Licensed by Pfizer Catalog No.S2789
Molecular Weight(MW): 312.37
Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM in cell-free assays, 20- to 100-fold less potent against JAK2 and JAK1.
8 Customer Reviews
-
(J) Western blotting analysis of HIF1α abundance in response to 100 nM tofacitinib. Quantification of HIF1α detected by Western blot is shown alongside, with data normalized to SMC1 intensity and HIF1α protein abundance in IL-2-maintained cytotoxic T lymphocytes.
Science, 2018, 11(526), doi: 10.1126/scisignal.aap8112. Tofacitinib (CP-690550,Tasocitinib) purchased from Selleck.
Effects of CP-690550 on NKTCL cell lines. NK-S1, KHYG-1 cells were treated with CP-690550 for 48 hours, and the effect on STAT5 phosphorylation was evaluated by Western blotting.
Cancer Discov 2012 2(7), 591-7. Tofacitinib (CP-690550,Tasocitinib) purchased from Selleck.
-
AE cells were treated with vehicle control (DMSO), a MEK inhibitor (PD98059), a PI3K inhibitor (LY294002) or a JAK2 inhibitor (CP690550) at indicated concentrations for 24 hours, followed by lysis for immunoblotting.
Blood 2012 120(4), 709-19. Tofacitinib (CP-690550,Tasocitinib) purchased from Selleck.
(d) Immunoblots of indicated proteins in primary EITL cells treated with PD0325901, Tofacitinib and Trametinib for two and Stattic for 24 h at indicated concentrations.
Leukemia, 2016, 30(6):1311-9. Tofacitinib (CP-690550,Tasocitinib) purchased from Selleck.
-
TRAP-positive multinucleated cell differentiation depends on JAK and is inhibited by tofacitinib in vitro. Effect of tofacitinib on the differentiation of TRAP-positive multi-nucleated cells in vitro (n =3 wells/experiment). Original magnification x 100.
Arthritis Rheumatol 2014 66(1), 121-9. Tofacitinib (CP-690550,Tasocitinib) purchased from Selleck.
BMDM from wild time mice were incubated with the concentrations of Ruxolitinib (R) or Tasocitinib (T) indicated, then stimulated for 30 min with (+) or without (-) 500 units/ml IFNβ. The cells were lysed and 30 ug of cell extract protein subjected to SDS-PAGE and immunoblotted with an antibody that recognizes STAT1 phosphorylated at Tyr-701 (p-STAT1) and an antibody that recognizes all forms of STAT1.
J Biol Chem 2012 287(41), 34825-35. Tofacitinib (CP-690550,Tasocitinib) purchased from Selleck.
-
Effect of a panel of IFN inhibitors on BUNΔNSs virus growth in A549 cells. The inhibitor panel consists of small molecules that target the IKK2 (TPCA-1) and TBK1 (BX795, MRT6884, MRT6707) components of the IFN induction pathway and JAK1 (Cyt387, AZD1480, Ruxolitinib, Tofacitinib) a component of the IFN signaling pathway. Effect of the inhibitors was compared with A549 cells constitutively expressing viral IFN antagonists that block IFN production (BVDV-Npro) or IFN signaling (PIV5-V). Effect of various inhibitor concentrations on plaque size formation. Plaques were visualized 2 days post-infection by crystal violet staining.
PLoS One 2014 9(11), e112014. Tofacitinib (CP-690550,Tasocitinib) purchased from Selleck.
Role of tyrosine kinase Jak2 in NHE1 activation. Mean (WSEM) pHi increases upon introduction of 350mOsM medium with AG490 (example shown in C), Jak Inhibitor I (Jak Inhibit I; 1uM), CP690550 (1uM), and control (vehicle alone, with 0.1% ethanol for AG490, 0.01% DMSO for Jak Inhibitor I and CP690550). Bars that do not share the same letter are significantly different by one-way ANOVA and Tukey–Kramer Multiple Comparisons Test (P < 0.05).
Tofacitinib (CP-690550,Tasocitinib) purchased from Selleck.
Purity & Quality Control
Choose Selective JAK Inhibitors
Biological Activity
| Description | Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM in cell-free assays, 20- to 100-fold less potent against JAK2 and JAK1. | |||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Targets |
|
|||||||||||||||||||||||||||||||||||||
| In vitro |
CP-690550 is a specific, orally inhibitor of JAK3, it is 20- to 100-fold less potent for JAK2 and JAK1 with IC50 of 20 nM and 112 nM, respectively. CP-690550 doesn't have potent activity against 30 other kinases (all median IC50 > 3000 nM). CP-690,550 inhibits IL-2–induced proliferation with 30-fold greater potency than its effects on GM-CSF–induced proliferation. [1] CP-690550 effectively inhibits a murine mixed lymphocyte reaction (MLR) (IC50 = 91 nM). [2] CP-690550 potently inhibits IL-4 induced upregulation of CD23 (IC50=57 nM) and class II major histocompatibility complex (MHCII) expression (IC50=71 nM) on murine B cells. [3] A recent research indicates low dose of CP-690550 accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation. [4] |
|||||||||||||||||||||||||||||||||||||
| Cell Data |
|
|||||||||||||||||||||||||||||||||||||
| In vivo | In a murine model of heterotopic heart transplantation (DBA2 donor heart into C57/BL6 host), CP-690550 results in a dose-dependent increase in survival of transplanted hearts.The EC50 (drug concentration in blood at which 50% of mice will maintain their graft for >28 days) to be ~60 ng/mL.CP-690550 prevents rejection of allogeneic kidneys in nonhuman primate (NHPs, macaca fascicularis) (MST of 62 and 83 days for the 50 to 100 ng/ml groups and 200 to 400 ng/ml groups, respectively). [1] Mice chronically dosed with CP-690550 (1.5-15 mg/kg/day) demonstrates dose and time-dependent alterations in lymphocyte subsets when examined by flow cytometry. The most dramatic change observed is a 96% reduction in splenic NK1.1+TCRb-cell numbers following 21 days of treatment. Delayed-type hypersensitivity (DTH) responses in sensitized mice are reduced in a dose-dependent manner following treatment with CP-690550 (1.87–30 mg/kg, s.c.). Extended survival of neonatal Balb/c hearts implanted into the ear pinna of MHC mismatched C3H/HEN mice is observed with CP-690550 monotherapy (10–30 mg/kg/day), but improved upon combination with cyclosporin (10 mg/kg/day). [2] |
Protocol
| Kinase Assay: |
+ Expand
JAK3 Kinase Assay: A fragment encoding the catalytic domain of human JAK3 (785aa to 1125aa, JH1 catalytic domain) is amplified by PCR from the full length cDNA and cloned into the EcoRI site of the baculovirus transfer vector pVL1393. Recombinant baculovirus is used to infect Sf9 (Spodoptera frugipedra) cells and recombinant GSTJAK3 fusion protein is isolated on glutathione sepharose. The fusion protein is eluted with reduced glutathione and stored in buffer containing 50 mM Tris, pH 7.5, 10 mM DTT and 10% glycerol. JAK3 kinase activity is measured by ELISA as follows: Plates are coated overnight with a random L-glutamic acid and tyrosine co-polymer (4:1) (100 ug/mL). The plates are washed and recombinant JAK3 JH1:GST (100 ng/well) with or without inhibitors is incubated at room temperature for 30 minutes, after which HRP-conjugated PY20 anti-phosphotyrosine antibody (ICN) is added and developed by TMB (3,3',5,5'-tetramethylbenzidine). Other kinases (Table 1) are produced in E. coli or in insect cells, depending upon what is found to be optimal for the given kinase. The catalytic activity of tyrosine kinases is easured using the aftorementioned ELISA, whereas serine/threonine kinases are assayed using radioactive enzyme assays. |
|---|---|
| Cell Research: |
+ Expand
|
| Animal Research: |
+ Expand
|
Solubility (25°C)
| In vitro | DMSO | 62 mg/mL warmed (198.48 mM) |
|---|---|---|
| Water | Insoluble | |
| Ethanol | Insoluble | |
| In vivo | Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing. |
5mg/mL |
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Information
| Molecular Weight | 312.37 |
|---|---|
| Formula | C16H20N6O |
| CAS No. | 477600-75-2 |
| Storage | powder |
| in solvent | |
| Synonyms | N/A |
Bio Calculators
Molarity Calculator
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Dilution Calculator
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Molarity Calculator
Clinical Trial Information
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03598959 | Not yet recruiting | Extranodal NK/T-cell Lymphoma | Sichuan University | January 1 2019 | Phase 2 |
| NCT03681275 | Not yet recruiting | Diaphragm Injury | Stanford University | December 1 2018 | Phase 1 |
| NCT03580343 | Not yet recruiting | Uveitis|Scleritis | Washington University School of Medicine | September 2018 | Phase 2 |
| NCT03486457 | Recruiting | Psoriatic Arthritis | Pfizer | August 10 2018 | Phase 3 |
| NCT03502616 | Recruiting | Ankylosing Spondylitis | Pfizer | June 7 2018 | Phase 3 |
| NCT03000439 | Recruiting | Arthritis Juvenile Idiopathic | Pfizer | May 10 2018 | Phase 3 |
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Frequently Asked Questions
-
Question 1:
I was just wondering what the main differences between S2789 and S5001?
-
Answer:
S2789(Tofacitinib (CP-690550)) is the base form of S5001 (Tofacitinib (CP-690550) Citrate). The biological activity of these two compounds are same. The S5001 (Tofacitinib (CP-690550) Citrate) is more suitable for oral administration.
